Core Insights - Elanco Animal Health celebrates the second annual National Parvo Awareness Day to raise awareness about canine parvovirus, a highly contagious and often fatal disease affecting puppies [1][9] - The Canine Parvovirus Monoclonal Antibody (CPMA) has received conditional approval from the USDA and has significantly improved survival rates for infected puppies, with a 93% survival rate reported [5][9] - Elanco aims to save 1 million puppies from parvovirus by 2030 and emphasizes the importance of making CPMA widely available, especially in resource-strained shelter environments [6][9] Company Initiatives - Elanco has launched ParvoTrack, a real-time online tool for tracking parvovirus outbreaks, allowing pet owners and veterinarians to self-report cases and receive alerts [6][9] - The company has reported thousands of parvo cases since the launch of ParvoTrack, with significant outbreaks noted in states like Texas, Arizona, and Florida [6][9] - Elanco is committed to increasing access to CPMA and encourages clinics and shelters to adopt this treatment to combat parvovirus effectively [6][7] Treatment Impact - Puppies treated with CPMA spend an average of 1.87 fewer days in the hospital, alleviating the emotional burden on veterinary staff and facilitating quicker reunions with families [5][9] - Real-world usage of CPMA has shown a 93% survival rate for parvo-infected puppies, marking a significant advancement in treatment options [5][9] - Testimonials from veterinarians highlight the positive change in attitudes towards parvovirus outbreaks since the introduction of CPMA, emphasizing its critical role in treatment [7][9]

Company Overview - Elanco Animal Health Incorporated (ELAN) shares increased by 12.6% to close at $9.38, following a relief rally in global markets due to a 90-day pause on tariff hikes by the United States [1] - The stock had previously experienced a 17% loss over the past four weeks [1] Earnings Expectations - Elanco is expected to report quarterly earnings of $0.31 per share, reflecting a year-over-year decline of 8.8% [2] - Revenue projections stand at $1.17 billion, which is a decrease of 3.1% compared to the same quarter last year [2] Stock Performance Insights - The consensus EPS estimate for Elanco has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [3] - Elanco currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [3] Industry Context - Elanco is part of the Zacks Medical - Outpatient and Home Healthcare industry, which includes other companies like Astrana Health, Inc. (ASTH) [3] - Astrana Health's consensus EPS estimate has decreased by 3.5% over the past month to $0.28, representing a year-over-year change of -9.7% [4] - Astrana Health also holds a Zacks Rank of 3 (Hold) [4]

Core Viewpoint - Elanco Animal Health Incorporated will announce its first quarter 2025 financial results on May 7, 2025, and will hold a conference call to discuss the performance with the investment community and media [1][2]. Company Overview - Elanco Animal Health is a global leader in animal health, focusing on innovating and delivering products and services for the prevention and treatment of diseases in farm animals and pets [3]. - The company has a 70-year heritage in animal health and aims to create value for farmers, pet owners, veterinarians, stakeholders, and society [3]. - Elanco is committed to improving animal health while making a meaningful impact on local and global communities, driven by its vision of "Food and Companionship Enriching Life" and sustainability pillars [3].

GREENFIELD, Ind., March 17, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced changes to its Board of Directors that will reduce the Board size to 11 directors by the 2025 Annual Meeting of Shareholders: John P. (JP) Bilbrey, Kathy Turner and Craig Wallace have each informed the Board they will not stand for re-election at the conclusion of their terms at the 2025 Annual Meeting of Shareholders. William F. (Bill) Doyle has resigned from the Board, effective immediately, in ...

Core Insights - Elanco Animal Health reported fourth-quarter revenue of $1.02 billion, a decrease of 1% on a reported basis but a 4% organic constant currency growth, surpassing the consensus estimate of $1.01 billion [1] - The company reported adjusted EPS of 14 cents, an increase from 8 cents year-over-year, but fell short of the consensus estimate of 15 cents [1] Pet Health Segment - Pet Health revenue reached $439 million, reflecting a 6% year-over-year increase, with a 3% price increase contributing to this growth, driven by strong performance in the global over-the-counter retail parasiticide business and new products like Zenrelia and Credelio Plus, although competitive pressures in the U.S. veterinary channel partially offset these gains [2] Farm Animal Segment - Farm Animal revenue was $570 million, showing a 7% decrease on a reported basis but a 2% increase on an organic constant currency basis, with a 3% contribution from price in the fourth quarter; strong demand for Experior and Rumensin in the U.S. and swine across multiple geographies supported the organic growth [3] Financial Metrics - Adjusted EBITDA was $177 million, marking a 7% increase, with an adjusted EBITDA margin of 17.4%, up 150 basis points [3] Future Guidance - For 2025, Elanco expects revenues between $4.45 billion and $4.51 billion, slightly below the consensus of $4.53 billion, and adjusted EPS in the range of 80-86 cents, compared to the consensus of 90 cents; the company anticipates a revenue headwind of approximately $110 million due to unfavorable foreign exchange rates [4] Management Commentary - The company is focused on accelerating organic constant currency revenue growth for 2025 and improving earnings potential while navigating a dynamic macroeconomic environment; adjustments made were primarily for incremental currency headwinds [5] Q1 2025 Expectations - For the first quarter of 2025, Elanco projects revenues of $1.16 billion to $1.18 billion, below the consensus of $1.21 billion, and adjusted EPS of 29-34 cents, compared to the consensus of 30 cents [6] Stock Performance - Elanco's stock is down 4.68% at $10.59 as of the last check on Tuesday [7]

D 2024 Earnings – Fourth Quarter February 25, 2025 2024 | Q4 Earnings Notices and Disclaimers Forward-Looking Statements. This presentation contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements concerning product launches and revenue from such products, our 2025 full year and first quarter guidance, long-term expectations, our expectations regarding debt levels, and expectations regarding our industry and our operations, performance ...

Financial Data and Key Metrics Changes - Fourth quarter revenue was $1.02 billion, representing a 1% reported decline, but organic constant currency growth was 4% [46] - Adjusted EBITDA for the fourth quarter was $177 million, an increase of $12 million on a reported basis [54] - Full year adjusted EPS came in at $0.91 compared to $0.89 in 2023, reflecting a slight growth [58] Business Line Data and Key Metrics Changes - Total Pet Health revenue increased by 6% in constant currency in the fourth quarter, with U.S. Pet Health growing by 2% and international Pet Health growing by 11% [47][48] - U.S. Farm Animal business achieved $223 million in sales, a 6% increase, driven by market expansion and increased share within the cattle business [49] - International Farm Animal revenue was flat, impacted by the Kexxtone recall and strategic changes in certain geographies [50] Market Data and Key Metrics Changes - The U.S. dermatology market is projected to surpass $2 billion, with Zenrelia capturing significant market share [80] - The global poultry demand showed sequential improvement, contributing to the overall growth despite challenges in swine economics in Asia [17][50] - The carbon market for Bovaer is estimated to be $2 billion, with strong demand from farmers and consumer product goods companies [38] Company Strategy and Development Direction - The company is focused on growth, innovation, and cash generation, with expectations of 4% to 6% organic constant currency revenue growth in 2025 [12][73] - Strategic divestiture of the aqua business has allowed for debt reduction and increased investments in product launches [10][20] - The company aims to leverage its comprehensive portfolio to enhance market share in both Pet Health and Farm Animal segments [22][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve sustained growth despite macroeconomic challenges, including foreign exchange impacts [14][13] - The management highlighted the importance of innovation and commercial execution in driving future revenue growth [72] - The company anticipates a positive revenue trajectory for Bovaer and other innovative products in the second half of 2025 [39][97] Other Important Information - The company achieved a net leverage ratio of 4.3 times at the end of the year, down from 5.6 times at the start of 2024 [20] - Operating cash flow for the full year was $541 million, representing 120% of adjusted net income [60] - The company plans to increase capital expenditures to support the expansion of its monoclonal antibody manufacturing facility [66] Q&A Session Summary Question: What is the expected penetration of Zenrelia by year-end 2025? - Management is optimistic about Zenrelia's growth trajectory, with significant adoption in U.S. vet clinics and plans for aggressive sampling programs to drive further penetration [80][84] Question: What factors contribute to the accelerating revenue growth in Q1 2025? - The growth is attributed to the ramp-up of Zenrelia and Credelio Quattro, alongside the absence of headwinds faced in the previous year [88][89] Question: What gives confidence in the innovation contribution for 2025? - The momentum from successful product launches like Experior and AdTab, along with the growth potential in the dermatology market, supports this confidence [96][97] Question: How is the commercialization strategy for Credelio Quattro different? - The strategy includes a strong DTC approach and leveraging the existing Credelio franchise's growth to enhance market penetration [116] Question: What is the expected impact of competition in the dermatology market? - Competition is acknowledged as a headwind, but the company remains confident in its growth potential due to unmet needs in the market [125][126]

Financial Data and Key Metrics Changes - Fourth quarter revenue was $1.02 billion, representing a 1% reported decline, but organic constant currency growth was 4% [46] - Adjusted EBITDA for the fourth quarter was $177 million, an increase of $12 million on a reported basis [54] - Full year adjusted EPS came in at $0.91 compared to $0.89 in 2023, reflecting a year-over-year growth [58] Business Line Data and Key Metrics Changes - Total Pet Health revenue increased 6% in constant currency in the fourth quarter, with U.S. Pet Health growing 2% and international Pet Health growing 11% [47][48] - U.S. Farm Animal business achieved $223 million in sales, a 6% increase, driven by cattle market expansion [49] - International Farm Animal revenue was flat, impacted by the Kexxtone recall and strategic changes in certain geographies [50] Market Data and Key Metrics Changes - The U.S. dermatology market is projected to surpass $2 billion, with Zenrelia capturing significant market share [80] - The global carbon market for Bovaer is estimated to be $2 billion, with strong demand from farmers [38] - The U.S. dairy farmers earned approximately $10 million in credits from using Rumensin in the fourth quarter [39] Company Strategy and Development Direction - The company is focused on growth, innovation, and cash generation, with expectations for 2025 organic constant currency revenue growth of 4% to 6% [12][73] - Strategic divestiture of the aqua business has allowed for debt reduction and increased investments in product launches [10][20] - The company aims to leverage its comprehensive portfolio to enhance market share in both Pet Health and Farm Animal sectors [22][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in accelerating fundamentals for 2025, despite challenges from foreign exchange impacts [14][72] - The company anticipates continued growth from innovation and a stabilization of its base business [13][42] - Management highlighted the importance of effective commercial execution and the positive reception of new product launches [72] Other Important Information - The company achieved a net leverage ratio of 4.3 times at the end of the year, down from 5.6 times at the start of 2024 [20] - The company launched five new U.S. product approvals in 2024, contributing to a robust innovation pipeline [28] - The company expects adjusted EBITDA for 2025 to be between $830 million and $870 million, factoring in foreign exchange headwinds [64] Q&A Session Summary Question: What is the expected penetration of Zenrelia by year-end 2025? - Management indicated that Zenrelia is experiencing strong adoption, with a focus on increasing clinic penetration through aggressive sampling and direct-to-consumer efforts [81][84] Question: What factors contribute to the accelerating revenue growth in Q1 2025? - Management noted that the growth is driven by the ramp-up of Zenrelia and Credelio Quattro, alongside the absence of headwinds faced in the previous year [88][89] Question: What gives confidence in the innovation contribution for 2025? - Management highlighted strong momentum from products like Experior and AdTab, as well as the growth potential in the dermatology market with Zenrelia and Quattro [96][97] Question: How is the early launch of Credelio Quattro performing? - Management reported positive initial momentum, with strong veterinarian interest and a comprehensive commercialization strategy in place [115][116] Question: What are the dynamics behind the surge in Galliprant sales? - Management attributed the surge to its strong safety profile and effective marketing strategies, expecting continued performance into 2025 [120] Question: How does the company view the competitive environment in dermatology? - Management acknowledged competition as a headwind but emphasized the growing market and unmet needs that present opportunities for growth [125][126]

Group 1 - Elanco Animal Health reported $1.02 billion in revenue for Q4 2024, a year-over-year decline of 1.5% [1] - The EPS for the same period was $0.14, compared to $0.08 a year ago, indicating an increase [1] - The revenue exceeded the Zacks Consensus Estimate of $1.01 billion by 0.83%, while the EPS fell short of the consensus estimate of $0.15 by 6.67% [1] Group 2 - Total Pet Health revenue was $439 million, surpassing the average estimate of $428.67 million, reflecting a year-over-year increase of 5.5% [4] - Total Contract Manufacturing revenue reached $11 million, exceeding the average estimate of $9.35 million, with a year-over-year growth of 22.2% [4] - Total Farm Animal revenue was $570 million, slightly below the average estimate of $575.40 million, showing a year-over-year decline of 6.6% [4] Group 3 - Elanco Animal Health shares have returned -8% over the past month, compared to the Zacks S&P 500 composite's -1.8% change [3] - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the broader market in the near term [3]

Core Viewpoint - Elanco Animal Health reported quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.15 per share, but showing an improvement from $0.08 per share a year ago, indicating a -6.67% earnings surprise [1] Financial Performance - The company posted revenues of $1.02 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.83%, although this represents a decline from year-ago revenues of $1.04 billion [2] - Over the last four quarters, Elanco has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - Elanco shares have declined approximately 8.3% since the beginning of the year, contrasting with the S&P 500's gain of 1.7% [3] - The current consensus EPS estimate for the upcoming quarter is $0.31 on revenues of $1.2 billion, and for the current fiscal year, it is $0.89 on revenues of $4.51 billion [7] Industry Outlook - The Medical - Outpatient and Home Healthcare industry, to which Elanco belongs, is currently ranked in the top 22% of over 250 Zacks industries, suggesting a favorable industry outlook [8]